CINECA IRIS Institutional Research Information System

BOCCADORO, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.446
EU - Europa 24.854
AS - Asia 14.039
SA - Sud America 723
AF - Africa 359
OC - Oceania 307
Continente sconosciuto - Info sul continente non disponibili 52
Totale 69.780
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.414
CN - Cina 8.238
IT - Italia 4.771
DE - Germania 3.005
SE - Svezia 2.617
IE - Irlanda 2.478
FR - Francia 1.921
RU - Federazione Russa 1.907
UA - Ucraina 1.675
KR - Corea 1.324
GB - Regno Unito 1.307
JP - Giappone 1.279
FI - Finlandia 1.267
AT - Austria 996
SG - Singapore 944
CA - Canada 780
IN - India 685
PL - Polonia 671
ES - Italia 594
VN - Vietnam 526
BR - Brasile 331
NL - Olanda 327
AU - Australia 265
TR - Turchia 235
HK - Hong Kong 223
MX - Messico 208
BE - Belgio 203
SN - Senegal 202
CH - Svizzera 197
GR - Grecia 186
DK - Danimarca 185
CO - Colombia 139
PT - Portogallo 112
TW - Taiwan 99
AR - Argentina 89
SA - Arabia Saudita 77
HU - Ungheria 67
TH - Thailandia 67
CZ - Repubblica Ceca 64
IL - Israele 64
BY - Bielorussia 61
NO - Norvegia 53
UZ - Uzbekistan 53
CL - Cile 49
EU - Europa 49
PE - Perù 48
MA - Marocco 41
NZ - Nuova Zelanda 41
RO - Romania 38
IR - Iran 37
ID - Indonesia 35
EG - Egitto 28
HR - Croazia 28
ZA - Sudafrica 28
RS - Serbia 25
PK - Pakistan 23
BO - Bolivia 21
BG - Bulgaria 20
EC - Ecuador 17
TN - Tunisia 17
AE - Emirati Arabi Uniti 16
PH - Filippine 15
MU - Mauritius 14
SI - Slovenia 14
UY - Uruguay 14
KZ - Kazakistan 13
VE - Venezuela 13
MK - Macedonia 12
MY - Malesia 12
BA - Bosnia-Erzegovina 11
CR - Costa Rica 9
KW - Kuwait 9
NG - Nigeria 9
EE - Estonia 8
JO - Giordania 8
LU - Lussemburgo 8
AM - Armenia 7
LT - Lituania 7
QA - Qatar 7
BD - Bangladesh 6
CU - Cuba 6
LK - Sri Lanka 6
PA - Panama 6
TT - Trinidad e Tobago 6
AL - Albania 5
DZ - Algeria 5
GE - Georgia 5
SK - Slovacchia (Repubblica Slovacca) 5
BN - Brunei Darussalam 4
GT - Guatemala 4
KE - Kenya 4
KY - Cayman, isole 4
MM - Myanmar 4
LB - Libano 3
NP - Nepal 3
AD - Andorra 2
AP - ???statistics.table.value.countryCode.AP??? 2
CI - Costa d'Avorio 2
CY - Cipro 2
GF - Guiana Francese 2
Totale 69.743
Salva come PNG Salva come JPEG
Città #
Beijing 5.398
Chandler 3.348
Dublin 2.444
Houston 2.258
Moscow 1.679
Ashburn 1.348
Fairfield 1.342
Jacksonville 1.132
Ann Arbor 1.094
Vienna 953
Villeurbanne 944
Medford 901
Wilmington 856
Princeton 829
Nyköping 804
Torino 801
Dearborn 712
Redwood City 694
Woodbridge 660
Florence 608
Seattle 573
Warsaw 553
Singapore 524
Cambridge 496
San Mateo 405
Milan 390
Tokyo 328
Pisa 313
Dong Ket 310
Shanghai 300
Fremont 284
Turin 270
Boardman 266
Hangzhou 258
Toronto 248
Ottawa 223
Boston 213
New York 210
Guangzhou 203
Nanjing 180
Duncan 174
Munich 149
London 143
Los Angeles 134
Norwalk 133
Madrid 129
Verona 125
Brussels 121
Rome 121
Düsseldorf 111
Washington 106
Hefei 104
Paris 103
Bologna 97
San Diego 97
Chicago 96
Helsinki 96
Falls Church 92
São Paulo 91
Zhengzhou 87
Chengdu 86
Nürnberg 82
Pune 79
Phoenix 77
Rochester 77
Saint Petersburg 74
Changsha 73
Istanbul 72
Wuhan 72
Barcelona 71
Sydney 67
Seoul 66
Lachine 65
Hebei 64
Hyderabad 62
Bogotá 60
Mountain View 59
Philadelphia 59
Central 58
Hong Kong 58
Portland 57
Mumbai 56
Taipei 54
Kunming 52
Amsterdam 51
Athens 50
Frankfurt am Main 50
Jinan 50
Xian 48
Nanchang 46
Padova 46
Tianjin 46
Shenyang 44
San Jose 43
Chennai 42
Indianapolis 42
Mcallen 42
Buenos Aires 40
Raritan 40
Lima 39
Totale 39.980
Salva come PNG Salva come JPEG
Nome #
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project 2.842
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 2.566
Alpha-2b recombinant interferon (Intron-A) as maintenance treatment in multiple myeloma. 1.681
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial 1.603
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial 1.449
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) 1.079
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma 781
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma 760
Melphalan hydrochloride for the treatment of multiple myeloma 684
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 562
Human myeloma: kinetics of the remission phase. 511
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma 482
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. 477
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 446
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors 442
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 414
Relevance of sample preparation for flow cytometry 400
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation 391
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 377
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension 371
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma 322
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. 320
Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. 298
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma 289
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 279
Corticosteroids can reverse severe imatinib-induced hepatotoxicity 277
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives 276
Extracellular vesicles as potential biomarkers of acute graft-vs.-host-disease 274
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 271
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma 252
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 247
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma 247
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) 246
EXTRACELLULAR VESICLES AS POTENTIAL BIOMARKER FOR ACUTE GVHD 229
CLINICAL IMPACT OF IMMUNOPHENOTYPIC REMISSION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MULTIPLE MYELOMA 227
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 226
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives 223
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results 220
Determining treatment intensity in elderly patients with multiple myeloma 218
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 208
A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. 208
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. 196
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 193
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma 191
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 191
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib 191
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 189
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 189
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study 187
FLAI induction regimen in elderly patients with acute myeloid leukemia 186
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma 184
Ruxolitinib in steroid refractory graft-vs.-host disease: A case report 183
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 182
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide 180
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 179
Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients 178
How is patient care for multiple myeloma advancing? 175
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 175
Risk of hepatitis B and efficacy of treatment with lamivudine in patients undergoing allogeneic stem cell transplant 173
International staging system for multiple myeloma. 172
Can pegylated interferon improve the outcome of polycythemia vera patients? 172
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis 172
International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. 170
Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia 169
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis 166
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. 165
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis 165
Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS 159
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 154
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when 152
CD38 as an immunotherapeutic target in multiple myeloma 149
null 148
Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma. 146
Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study 146
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma 146
Anemia in the Elderly: not Always what it Seems. 144
Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo) 143
A POST-REMISSION MAINTENANCE TREATMENT WITH LOW-DOSE CHEMOTHERAPY + RETINOIDS AND DIHYDROXYLATED VITAMIN D3 MAY IMPROVE THE SURVIVAL OF POOR-PROGNOSIS AML/MDS PATIENTS 143
Emerging drugs and combinations to treat multiple myeloma 141
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the italian bone marrow donor registry. 141
High CR Rate and Prolonged EFS in aaIPI 2 – 3 Diffuse Large B-Cell Lymphoma Following High-Dose Sequential Chemotherapy and In Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen): Results of a Prospective Phase II Multicenter Study Sponsored by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) 141
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. 140
Therapeutic monoclonal antibodies and antibody products: Current practices and development in multiple myeloma 136
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 135
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial 135
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients 134
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies 134
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial 134
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 133
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts 130
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. 130
ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS 130
Magic pills: new oral drugs to treat chronic lymphocytic leukemia 128
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients 126
Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry 125
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes. 125
A practical update on the use of bortezomib in the management of multiple myeloma 124
Novel Immunotherapies for Multiple Myeloma 124
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma 124
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. 123
Totale 32.871
Salva come PNG Salva come JPEG
Categoria #
all - tutte 175.231
article - articoli 0
book - libri 0
conference - conferenze 49.826
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 225.057
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208.834 0 296 520 939 681 1.675 989 692 1.130 771 688 453
2020/20219.404 781 462 709 549 905 647 757 606 1.012 752 1.087 1.137
2021/20229.712 449 385 413 783 497 365 1.217 556 348 930 1.685 2.084
2022/202313.402 1.207 995 464 1.244 1.183 2.838 1.085 994 1.325 555 830 682
2023/20249.588 863 1.241 580 640 665 1.002 548 616 180 681 1.229 1.343
2024/20251.406 1.201 205 0 0 0 0 0 0 0 0 0 0
Totale 72.207